Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-7262 · 2 trials · 2 indications
Blood samples will be collected at baseline and at Week 8 to assess the mean percent change from baseline in Lp(a).
Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.
Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will receive MK-7262 placebo + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| enlicitide monotherapy | ACTIVE_COMPARATOR | Participants will receive enlicitide + MK-7262 placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 monotherapy | EXPERIMENTAL | Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 + enlicitide | EXPERIMENTAL | Participants will receive MK-7262 + enlicitide orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 | EXPERIMENTAL | Participants will receive MK-7262 orally. |
| Enlicitide | EXPERIMENTAL | Participants will receive enlicitide orally. |
| MK-7262 plus Enlicitide | EXPERIMENTAL | Participants will receive MK-7262 and enlicitide orally. |
| Name | Type | Description |
|---|---|---|
| MK-7262 | DRUG | Oral Coated Tablet |
| Enlicitide | DRUG | Oral Coated Tablet |
| Placebo for MK-7262 | DRUG | Oral Coated Tablet |
| Placebo for enlicitide | DRUG | Oral Coated Tablet |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has Lp(a) ≥ 150 nmol/L * Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study Exclusion Crite...
MK-7262 is an investigational small molecule being studied for use in people with high lipoprotein(a) and in healthy participants. It is being evaluated in clinical trials for its effects on lipoprotein(a) levels. The drug is not yet approved and remains in clinical development.
MK-7262 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials of MK-7262 in the United States and Japan.
MK-7262 is in Phase 1 and Phase 2 clinical trials. One Phase 1 study in healthy participants is active but not recruiting, and one Phase 2 study in participants with high lipoprotein(a) is currently recruiting. The drug is investigational and not FDA approved.
MK-7262 is being studied in two trials. NCT07614984 is a Phase 2 trial in participants with high lipoprotein(a), enrolling 750 people in the United States and Japan. NCT07619443 is a Phase 1 trial in healthy participants, enrolling 30 people in the United States.
MK-7262 is not the same as enlicitide. The two drugs are being studied together in clinical trials, including NCT07614984 and NCT07619443, which evaluate MK-7262 and enlicitide in combination. MK-7262 is a separate investigational compound developed by Merck.